Posts by: Alice Melão

News

The Phase 2 clinical trial assessing Moleculin Biotech‘s STAT3 inhibitor, WP1220, for the topical treatment of cutaneous T-cell lymphoma (CTCL) lesions has enrolled the first two participants. The trial, to assess WP1220‘s safety and ... Read more

March 26, 2019

Trials to Test Abexinostat in Heavily Treated DLBCL, Follicular Lymphoma

News

Xynomic Pharma is preparing two new Phase 2 trials in China to explore the activity of its investigational HDAC inhibitor, abexinostat, as third-line therapy for diffuse large B-cell lymphoma (DLBCL) ... Read more

February 22, 2019

FDA OKs Phase 1 Trial to Test TJC4 in Solid Tumors, Lymphoma

News

I-Mab Biopharma is planning the first-in-human U.S. clinical study evaluating the safety, tolerability, and efficacy of its investigational candidate TJC4 as a treatment for solid tumors and lymphoma. The Phase ... Read more

February 4, 2019

2 Small RNA Molecules Suppress Lymphoma, Leukemia Development, Mouse Study Suggests

News

Two small non-coding RNA molecules — miR-146a and miR-146b — appear to protect against the development of blood cancers such as B-cell lymphoma and acute myeloid leukemia, a mouse study suggests. These ... Read more

February 1, 2019February 1, 2019

Allogene’s Donor-derived CAR T-cell Therapy Cleared for Clinical Testing on Non-Hodgkin’s Lymphoma

News

Allogene Therapeutics and its partner Servier will soon launch a Phase 1/2 trial to assess the investigational cell therapy ALLO-501 in non-Hodgkin’s lymphoma patients who failed prior therapies, after the U.S. Food and Drug ... Read more

January 24, 2019

Imbruvica-Opdivo Combination Shows Promise in Richter’s Transformation

News

A combination of Imbruvica (ibrutinib) and Opdivo (nivolumab) reduced tumor burden in 65% of patients with Richter’s transformation — a kind of diffuse large B-cell lymphoma (DLBCL) with very poor prognosis, derived ... Read more

January 23, 2019

Genetic Profiling Identifies DLBCL Patients in Need of More Aggressive Treatment, Study Reports

News

Investigators in the U.K. have found a way to identify diffuse large B-cell lymphoma (DLBCL) patients who are less likely to respond to standard therapies and may require more aggressive ... Read more

January 15, 2019

Volcani Center to Request Patent Coverage for Cannabis-based CTCL Therapy

News

Israel’s Volcani Center plans to submit new patent applications covering the use of a unique formulation of active compounds extracted from the cannabis plant as treatment for cutaneous T-cell lymphoma (CTCL). Further ... Read more

January 14, 2019

Burkitt’s Lymphoma/Leukemia Patients Being Recruited for CPI-613 Phase 2 Trial

News

Rafael Pharmaceuticals is currently enrolling patients with relapsed or refractory Burkitt’s lymphoma/leukemia in a Phase 2 trial to assess the potential of its lead candidate CPI-613. The study (NCT03793140) is ... Read more

January 11, 2019

Epizyme Planning to Request FDA’s Accelerated Approval of Tazemetostat for Follicular Lymphoma Patients

News

Epizyme plans to ask the U.S. Food and Drug Administration (FDA) for accelerated approval of tazemetostat as a treatment for people with relapsed or refractory follicular lymphoma with or without EZH2 activating mutations. ... Read more